PharmaCyte Biotech, Inc. (PMCB) Key Metrics
PMCB valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $3.7M
- Enterprise value
- −$24.0M
- P/E (TTM)
- —
- Forward P/E
- 7.0
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 0.2 10-yr median 0.4
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 0.68
PMCB key metrics, FY2017–FY2026
Fiscal year ended April 30, 2026 · U.S. dollarsPMCB valuation Price multiples at each fiscal year-end price.
PMCB returns How much profit the business earns on the capital it uses.
PMCB per-share figures Results divided by the shares outstanding at year-end.
PMCB financial health Debt, liquidity and how easily interest is covered.
PMCB valuation history
PMCB returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
PMCB debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
PMCB cash returned to shareholders
PMCB price vs earnings per share
PMCB key metrics
FY2017–FY2026| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $6.0M | $9.1M | $20.3M | $56.9M | $36.2M | — | — | — | — | — |
| Enterprise value | −$31.0M | −$6.4M | −$29.9M | −$11.1M | −$49.2M | — | — | — | — | — |
| P/E ratio | — | 0.3 | 60.9 | — | — | — | — | — | — | — |
| Price / book | 0.2 | 0.2 | 0.5 | 0.8 | 0.4 | — | — | — | — | — |
| Earnings yield | −321.1% | 337.3% | 1.6% | −7.6% | −11.7% | — | — | — | — | — |
| Free cash flow yield | −85.2% | −32.8% | −10.6% | −6.7% | −11.4% | — | — | — | — | — |
| Dividend yield | 4.1% | 12.4% | 110.6% | — | — | — | — | — | — | — |
| Shareholder yield (dividends + buybacks) | 10.7% | 287.8% | 328.9% | 23.8% | 0.0% | — | — | — | — | — |
| Share price at fiscal year-end | $0.72 | $1.24 | $2.12 | $2.92 | $2.33 | $26.55 | $36.75 | $61.50 | $81.00 | $116.85 |
| Per share | ||||||||||
| Revenue per share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — | — | — |
| Earnings per share | −$2.32 | $4.18 | $0.03 | −$0.22 | −$0.27 | — | — | — | — | — |
| Operating cash flow per share | −$0.62 | −$0.41 | −$0.22 | −$0.19 | −$0.27 | — | — | — | — | — |
| Free cash flow per share | −$0.62 | −$0.41 | −$0.22 | −$0.19 | −$0.27 | — | — | — | — | — |
| Cash per share | $4.43 | $2.12 | $5.24 | $3.49 | $5.50 | — | — | — | — | — |
| Book value per share | $3.97 | $7.08 | $4.12 | $3.73 | $5.79 | — | — | — | — | — |
| Tangible book value per share | $3.97 | $6.87 | $3.96 | $3.55 | $5.56 | — | — | — | — | — |
| Dividends per share | $0.03 | $0.15 | $2.34 | — | — | — | — | — | — | — |
| Capex per share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — | — | — |
| Shares outstanding | 8.4M | 7.3M | 9.6M | 19.5M | 15.5M | — | — | — | — | — |
| Change in shares outstanding | +14.3% | −23.5% | −50.8% | +25.6% | — | — | — | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −45.6% | 67.1% | 0.6% | −5.3% | −8.8% | −60.4% | −75.6% | −75.3% | −98.6% | −60.8% |
| Return on invested capital (ROIC) | — | −26.9% | — | −111.2% | −76.7% | −79.2% | −83.7% | −70.2% | −118.2% | −76.1% |
| Return on assets (ROA) | −38.1% | 53.3% | 0.5% | −5.3% | −8.6% | −52.3% | −64.1% | −66.7% | −90.6% | −56.2% |
| Return on tangible assets | −41.5% | 57.2% | 0.6% | −6.2% | −4.9% | −92.1% | −146.2% | −182.1% | −238.5% | −86.8% |
| Income quality (OCF / net income) | — | −0.10 | −6.45 | — | — | — | — | — | — | — |
| Financial health | ||||||||||
| Total debt | — | — | — | — | — | $50,805 | $75,200 | — | — | — |
| Cash & short-term investments | $37.1M | $15.5M | $50.2M | $68.0M | $85.4M | $2.2M | $2.5M | $515,253 | $1.1M | $3.5M |
| Net debt | −$37.1M | −$15.5M | −$50.2M | −$68.0M | −$85.4M | −$2.2M | −$2.4M | −$515,253 | −$1.1M | −$3.5M |
| Debt / equity | — | — | — | — | — | 0.01 | 0.01 | — | — | — |
| Debt / assets | — | — | — | — | — | 0.01 | 0.01 | — | — | — |
| Current ratio | 45.28 | 7.68 | 6.80 | 116.18 | 121.38 | 3.14 | 1.01 | 0.88 | 1.99 | 6.10 |
| Quick ratio | 45.28 | 7.68 | 6.80 | 116.18 | 121.38 | 3.14 | 1.01 | 0.88 | 1.99 | 6.10 |
| Working capital | $36.6M | $19.5M | $43.0M | $67.6M | $84.8M | $1.6M | $6,248 | −$89,447 | $639,697 | $3.0M |
| Invested capital | −$3.8M | $36.4M | −$10.7M | $4.7M | $4.5M | $4.5M | $2.7M | $4.5M | $4.7M | $4.6M |
| Tangible asset value | $35.0M | $50.3M | $38.0M | $69.1M | $86.4M | $3.1M | $1.5M | $1.5M | $2.2M | $4.5M |
| Net current asset value | $25.6M | $19.1M | $30.1M | $67.6M | $84.8M | $1.6M | −$40,034 | −$89,447 | $639,697 | $3.0M |
| Graham number | — | $25.81 | $1.80 | — | — | — | — | — | — | — |
| Graham net-net per share | $3.04 | $2.05 | $3.11 | $3.46 | $5.46 | — | — | — | — | — |
| Capital allocation | ||||||||||
| Dividends paid | $246,005 | $1.1M | $22.5M | — | — | — | — | — | — | — |
| Share buybacks (net) | $401,625 | $25.0M | $44.4M | $13.6M | $0 | — | $1 | — | $0 | $0 |
| Dividend payout ratio | — | 3.7% | — | — | — | — | — | — | — | — |
| Capex / depreciation | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||||||||
| Receivables turnover | 0.00 | 0.00 | — | — | — | — | — | — | — | — |
| Payables turnover | — | — | — | — | — | — | — | — | 0.00 | 0.00 |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average receivables | $2.0M | $3.7M | — | — | — | — | — | — | — | — |
| Average payables | $335,153 | $394,286 | $258,825 | $166,821 | $188,811 | $179,052 | $153,864 | $237,253 | $359,110 | $350,804 |
| Intangibles / total assets | 0.0% | 2.8% | 2.6% | 4.8% | 3.9% | 47.9% | 57.6% | 61.4% | 55.3% | 41.0% |
Computed from PMCB's annual financial statements (latest annual report filed July 29, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
PMCB valuation and financial ratios
PharmaCyte Biotech earned a return on equity of −45.6% in fiscal 2026. It returned $0.6 million to shareholders: $0.2 million in dividends and $0.4 million in share buybacks.
See the PMCB income statement, the PMCB chart for price history, or the PMCB stock overview for the latest quote and news.
PMCB key metrics FAQ
What is PharmaCyte Biotech's return on equity?
PharmaCyte Biotech's return on equity (ROE) was −45.6% in fiscal 2026: net income of -$19.4 million on average shareholders' equity of $42.6 million.
What is PharmaCyte Biotech's dividend yield?
PharmaCyte Biotech paid $0.2 million in dividends in fiscal 2026 ($0.03 per share), a payout ratio of —.
Does PharmaCyte Biotech buy back its shares?
Yes. PharmaCyte Biotech spent $0.4 million on net share repurchases in fiscal 2026 Shares outstanding changed +14.3% over the year, to 8.4M..
What is PharmaCyte Biotech's free cash flow yield?
PharmaCyte Biotech generated -$5.2 million of free cash flow in fiscal 2026, a free cash flow yield of −85.2% on its market value at year-end ($6.0 million).
What is PharmaCyte Biotech's current ratio?
PharmaCyte Biotech's current ratio was 45.28 at the end of fiscal 2026: current assets were 45.28 times current liabilities.